ArticleJournal of family medicine and primary care2025
Variation in cardiovascular risk marker profile in treated diabetes mellitus patients with different body composition.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite treatment, patients with type 2 diabetes mellitus (T2D) are at risk of cardiovascular disease (CVD). Obesity is a separate risk factor of insulin resistance and CVD. The adipokine adipsin links adiposity, insulin resistance and inflammation. Heart type fatty acid binding protein (FABP3) protects against metabolic syndrome. Previously, the link between adipsin and FABP3 with body composition in diabetes patients on treatment has not been addressed. Therefore, in the present study, we have compared the levels of FABP3, adipsin, and their association with inflammation and body composition in T2D patients with high and normal BMI based on the Asian criteria of obesity. Materials and Methods: Adipsin and FABP3 were estimated by ELISA. Body composition was digitally recorded in Department of Physiology. Comparison was done by one-way-ANOVA against healthy controls. Results: Adipsin and TNF α were significantly increased, while FABP3 was decreased in high BMI T2D than healthy control. Normal BMI T2D had significant central obesity which explains their higher adipsin level. Conclusion: T2D patients exhibit different CVD risk profile linked to different levels markers such as adipsin and FABP3. This is explained better by the difference in body fat distribution compared to BMI alone. The treatment should target improvement based on new markers and body composition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.